Groupama Asset Managment Purchases 22,255 Shares of Medtronic PLC $MDT

Key Points

• Groupama Asset Managment increased its Medtronic stake by 62.9%, buying 22,255 shares to hold 57,642 shares worth about $5.49 million per its latest 13F filing.
• Other major institutions also added large positions — including a new Norges Bank stake (~$1.43 billion) and big increases from Barclays, Schroder and Wellington — leaving roughly 82.06% of Medtronic stock held by hedge funds and institutional investors.
• An insider sale (EVP Harry Skip Kiil sold 52,524 shares) coincided with a modest quarterly beat (EPS $1.36 vs. $1.34; revenue $9.02B), FY26 EPS guidance of 5.620–5.660, and a declared quarterly dividend of $0.71 (3.3% yield; ex-dividend Mar 27).

Groupama Asset Managment boosted its position in Medtronic PLC (NYSE:MDT - Free Report) by 62.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 57,642 shares of the medical technology company's stock after acquiring an additional 22,255 shares during the period. Groupama Asset Managment's holdings in Medtronic were worth $5,490,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Norges Bank bought a new position in Medtronic during the second quarter worth about $1,432,698,000. Barclays PLC raised its position in shares of Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock valued at $650,604,000 after purchasing an additional 3,492,192 shares during the period. Schroder Investment Management Group raised its position in shares of Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company's stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the period. Guinness Asset Management LTD purchased a new stake in shares of Medtronic during the 3rd quarter valued at approximately $275,556,000. Finally, Wellington Management Group LLP boosted its holdings in Medtronic by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after buying an additional 2,658,981 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company's stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.26% of the company's stock.

Medtronic Stock Down 0.4%

MDT stock opened at $86.83 on Friday. The company's 50 day moving average is $97.05 and its 200 day moving average is $96.71. The stock has a market cap of $111.48 billion, a price-to-earnings ratio of 24.19, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the business posted $1.38 earnings per share. Medtronic's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

Analyst Ratings Changes

A number of equities analysts have recently commented on MDT shares. Piper Sandler reaffirmed a "neutral" rating on shares of Medtronic in a report on Monday, January 5th. William Blair upgraded Medtronic from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 6th. Wells Fargo & Company started coverage on Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 price objective on the stock. Weiss Ratings restated a "buy (b-)" rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Leerink Partners reiterated an "outperform" rating and set a $119.00 price target on shares of Medtronic in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Medtronic presently has a consensus rating of "Moderate Buy" and an average target price of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.